Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Employees

20,700

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-05	9.610 $	-6.88%	494,124
25-12-04	10.32 $	+4.77%	569,843
25-12-03	9.850 $	+2.07%	410,965
25-12-02	9.650 $	-2.33%	459,999
25-12-01	9.880 $	+11.26%	1,074,717

Delayed Quote Toronto S.E., December 05, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.930USD

Average target price

7.167USD

Spread / Average Target

+3.42%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
9.610 ^CAD	-6.88%		+8.22%	-17.30%

12-02	Bausch Health Companies Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 10:50 AM
12-01	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Capitalization	2.57B 2.21B 2.07B 1.93B 3.56B 231B 3.87B 24.18B 9.34B 109B 9.64B 9.43B 399B	P/E ratio 2025 *	5.62x	P/E ratio 2026 *	4.82x
Enterprise value	21.8B 18.74B 17.55B 16.36B 30.22B 1,962B 32.87B 205B 79.27B 926B 81.81B 80.06B 3,388B	EV / Sales 2025 *	2.14x	EV / Sales 2026 *	1.93x
Free-Float	88.99%	Yield 2025 *	-	Yield 2026 *	-

12-02	Bausch Health Companies Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 10:50 AM
12-01	Sector Update: Health Care Stocks Decline Late Afternoon	MT
12-01	Sector Update: Health Care Stocks Decline Monday Afternoon	MT
12-01	TSX Down 140 Points at Midday With Info Tech The Worst Performer	MT
12-01	Top Midday Stories: Nvidia's $2 Billion Stake in Synopsys; Starbucks' Nearly $39 Million Fine; Goldman Sachs to Buy Innovator Capital for $2 Billion	MT
12-01	Bausch Health's Solta Medical Unit Acquires Chinese Distribution Partner Wuhan Shibo Zhenmei Technology; Shares Rise	MT
12-01	Bausch Health's Solta Medical Unit Acquires Chinese Distribution Partner Wuhan Shibo Zhenmei Technology	MT
12-01	Bausch Health Acquires Longtime Distribution Partner, Shibo Group, to Boost China Presence	MT
12-01	Bausch Health Brief: Bausch Health's Aesthetics Business, Solta Medical, Buying Longtime Distribution Partner, Shibo Group, to Strengthen Presence in China	MT
11-24	Bausch Health announces launch of offers to exchange certain existing senior secured notes	RE
11-24	Bausch Health Launches Exchange Offer for 2028 Secured Notes	MT
10-30	TSX ends higher as gold rally boosts metal-mining shares	RE
10-30	TSX up 120 Points at Midday With Healthcare The Best Performer	MT

10-29	Needham Keeps Hold on Bausch + Lomb After Q3, Says Would Like Clarity on Bausch Health Separation	MT
10-22	RBC Maintains Market Perform Rating, US$10 Price Target on Bausch Health Companies	MT
07-31	RBC Maintains US$10 Price Target, Sector Perform Rating on Bausch Health	MT
04-21	BofA Cuts Price Target on Bausch Health to $5 From $7	MT
04-07	RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating	MT

Bausch Health Companies Inc. Stock Toronto S.E.

Equities

BHC

CA0717341071

Pharmaceuticals

Valuation: Bausch Health Companies Inc.

Chart: Bausch Health Companies Inc.

Latest news: Bausch Health Companies Inc.

Last Transcript: Bausch Health Companies Inc.

Analysts' recommendations: Bausch Health Companies Inc.

Press Releases: Bausch Health Companies Inc.

News in other languages: Bausch Health Companies Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Bausch Health Companies Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-19	Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference	AQ
10-30	Bausch: Q3 Earnings Snapshot	AQ
09-08	Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage Non-Surgical System	AQ
09-01	Bausch Health Launches YUN Probiotherapy ACN Skincare Line in Poland	AQ
08-27	Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025	AQ

02-20	En direct des marchés : Schneider rit, Carrefour pleure et Apple sort un iPhone "abordable"
02-20	Joyeux anniversaire, Donald
24-10-18	MÄRKTE USA/Rekordjagd geht weiter - Netflix mit starken Zahlen
24-10-18	MÄRKTE USA/Auszeit nach Rekordjagd - Netflix mit starken Zahlen
24-10-18	MÄRKTE USA/Wall Street bleibt dank Netflix in Rekordnähe

1 day	-6.88%
1 week	+8.22%
Current month	+8.22%
1 month	+0.63%
3 months	-5.60%
6 months	+51.58%
Current year	-17.30%

1 week	9.16	10.52
1 month	8.35	10.52
Current year	5.91	11.97
1 year	5.91	12.07
3 years	5.45	15.43
5 years	5.1	43.97
10 years	5.1	165.77

Manager	Title	Age	Since
Thomas Appio CEO	Chief Executive Officer	62	2022-05-09
Jean-Jacques Charhon DFI	Director of Finance/CFO	59	2024-08-18
Mirza Dautbegovic COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Robert Power CHM	Chairman	68	2022-05-09
Thomas Appio BRD	Director/Board Member	62	2022-05-09
Amy Wechsler BRD	Director/Board Member	55	2016-06-13

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BAUSCH HEALTH COMPANIES INC.	-6.88%	+8.22%	-	-	2.57B
ELI LILLY AND COMPANY	-0.41%	-6.06%	+22.37%	+173.58%	905B
JOHNSON & JOHNSON	-0.27%	-2.41%	+35.05%	+12.95%	487B
ABBVIE INC.	-1.15%	-0.71%	+28.33%	+37.90%	400B
ROCHE HOLDING AG	+0.26%	+1.14%	+21.30%	+0.44%	330B
ASTRAZENECA PLC	+0.58%	-2.73%	+28.01%	+20.71%	281B
NOVARTIS AG	+0.19%	+2.49%	+18.48%	+24.80%	255B
MERCK & CO., INC.	-1.16%	-4.87%	-3.70%	-9.35%	248B
NOVO NORDISK A/S	+1.24%	-2.33%	-59.84%	-31.25%	214B
AMGEN INC.	-3.02%	-4.51%	+20.25%	+15.79%	178B
Average	-0.87%	-2.22%	+12.25%	+27.29%	366.28B
Weighted average by Cap.	-0.09%	-2.79%	+17.62%	+55.98%

	2025 *	2026 *
Net sales	10.18B 8.75B 8.2B 7.64B 14.12B 917B 15.36B 95.93B 37.04B 433B 38.23B 37.41B 1,583B	10.52B 9.04B 8.47B 7.89B 14.58B 947B 15.86B 99.07B 38.25B 447B 39.48B 38.63B 1,635B
Net income	461M 397M 371M 346M 640M 41.52B 696M 4.35B 1.68B 19.61B 1.73B 1.69B 71.7B	540M 464M 435M 405M 748M 48.57B 814M 5.08B 1.96B 22.94B 2.03B 1.98B 83.87B
Net Debt	19.23B 16.53B 15.48B 14.43B 26.66B 1,731B 29B 181B 69.93B 817B 72.17B 70.63B 2,989B	17.74B 15.25B 14.28B 13.31B 24.59B 1,596B 26.75B 167B 64.51B 754B 66.57B 65.15B 2,757B